The mission of the University of New Mexico Cancer Research and Treatment Center (UNM CRTC) is to use the expertise in basic and translational cancer research, epidemiology and clinical therapeutic and prevention trials to reduce the incidence and mortality of cancer in New Mexico. Participation in cooperative clinical trials sponsored by the National Cancer Institute (NCI) is a critical part of this mission. CRTC investigators have been contributing patients and scientific expertise to the NCI program since the center opened in 1975. The CRTC is part of the UNM School of Medicine (UNM SOM), one of eight components of the UNM Health Sciences Center (UNM HSC), the only academic medical center in the state. Among the CRTC's resources is the New Mexico Tumor Registry (NMRT), one of the original 12 NCI-funded Surveillance, Epidemiology and End Results (SEER) programs. The (NMTR) provides current and historical information about cancer in New Mexico's unique populations and is the world's largest database on cancer incidence and mortality in Hispanics and American Indians. New Mexico is characterized by ethnic diversity, unusual patterns of cancer incidence and mortality, poverty and poor access to medical services. The population is 38 percent Hispanic, 9 percent Native American, 2 percent African American and 51 percent Non-Hispanic White, Asian or """"""""other."""""""" New cancer diagnoses at the CRTC reflect this pattern; in 1998, CRTC patients were 34 percent Hispanic, 7 percent Native American, 2 percent African American and 57 percent Non-Hispanic White, Asian or """"""""other."""""""" The state's population is 49 percent male and 51 percent female; in 1998, newly diagnosed cancer patients were 42 percent male and 58 percent female. The CRTC is a member institution of the Southwest Oncology Group (SWOG) and the National Surgical Adjuvant Breast and Bowel Project (NSABP). An affiliate network of community physicians offers treatment and prevention studies from these groups to their patients in Albuquerque, Sante Fe, Farmington and Raton. The CRTC participates successfully in the large NCI-funded chemoprevention programs for breast and prostate cancer and the affiliate network has begun recruitment and outreach for NSABP's STAR trial. The CRTC pediatric oncologists are members of the Pediatric Oncology Group (POG), whose protocols are available to patients referred to the HSC by pediatricians and family practice physicians statewide. Designation as a Minority-Based Community Cancer Oncology Program will provide a stable and flexible funding base to increase accrual, strengthen the affiliate network and expand outreach to minority populations and the medically underserved.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J2))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of New Mexico
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Napoles, A; Cook, E; Ginossar, T et al. (2017) Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials. Adv Cancer Res 133:77-94
Ginossar, Tamar (2016) Predictors of Online Cancer Prevention Information Seeking Among Patients and Caregivers Across the Digital Divide: A Cross-Sectional, Correlational Study. JMIR Cancer 2:e2
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 52 publications